Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05420012 · ClinicalTrials.gov registry record · Phase 4
The Effect of Vericiguat on Peripheral Vascular Function, Patient Health Status and Inflammation
A Phase 4 study of Heart Failure and Heart Failure With Reduced Ejection Fraction (HFrEF), sponsored by Josef Stehlik.
- Completed
- Registry status
- Phase 4
- Development phase
- 26
- Enrollment target
- 2
- Study locations
NCT05420012: Completed Phase 4 study of Heart Failure and Heart Failure With Reduced Ejection Fraction (HFrEF), sponsored by Josef Stehlik.
NCT05420012 is a Phase 4 study of Heart Failure and Heart Failure With Reduced Ejection Fraction (HFrEF) that has completed, run by Josef Stehlik. The registered enrollment target is 26 participants, below the 2,049-participant average among 397 other Heart Failure trials with a reported enrollment target (99% lower). The trial reports 2 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05420012, a Phase 4 study of Heart Failure and Heart Failure With Reduced Ejection Fraction (HFrEF), has completed, sponsored by Josef Stehlik.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 26 participants
- Enrollment target
- 2
- Study locations
Study Summary
The concept that direct stimulation of soluble guanylate cyclase (sGC) could be a particularly effective approach to increase cyclic guanosine monophosphate (cGMP) in conditions of increased inflammation/oxidative stress, endothelial dysfunction, and reduced nitric oxide (NO) bioavailability. Thus, the aim of the proposed study is to examine the effect of Vericiguat on peripheral vascular function, inflammatory status, and patient health status. The study also aims to identify patients who are particularly likely to benefit from Vericiguat treatment and predict that these patients will be defined by baseline peripheral vascular dysfunction and high inflammatory state.
Primary Outcome
Change in vascular function using flow-mediated vasodilation (FMD) test. FMD is quantified as the maximal change in brachial artery diameter following cuff release, expressed as a percentage increase from pre-occlusion values (%FMD).
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Vericiguat
Study Locations (2)
Utah
- University of Utah Hospital - Salt Lake City
- Veterans Affairs Salt Lake City Health Care System (VAMC) - Salt Lake City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 26 participants |
| Start Date | 2023-05-01 |
| Est. Completion | 2024-10-24 |
| Phase | Phase 4 |
What the finished NCT05420012 record still lists
NCT05420012 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 26 participants, a relatively small participant target, below the 2,049-participant average among 397 other Heart Failure trials with a reported enrollment target (99% lower).
The record links to 2 conditions, with Heart Failure appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT05420012 reports a single indexed study location in Utah.
Frequently Asked Questions
What is clinical trial NCT05420012 about?
NCT05420012 is a clinical study titled "The Effect of Vericiguat on Peripheral Vascular Function, Patient Health Status and Inflammation". The concept that direct stimulation of soluble guanylate cyclase (sGC) could be a particularly effective approach to increase cyclic guanosine monophosphate (cGMP) in conditions of increased inflammation/oxidative stress, endothelial dysfunction, and reduced nitric oxide (NO) bioavailability. Thus, ...
What is the current status of trial NCT05420012?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 26 participants. The study started on 2023-05-01. Estimated completion is 2024-10-24.
What conditions does trial NCT05420012 study?
This clinical trial studies the following conditions: Heart Failure, Heart Failure With Reduced Ejection Fraction (HFrEF).
What interventions are being tested in trial NCT05420012?
The interventions under investigation include: Placebo (DRUG), Vericiguat (DRUG).
Who is sponsoring clinical trial NCT05420012?
This trial is sponsored by Josef Stehlik, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05420012 being conducted?
This trial has 2 study locations across Utah. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Heart Failure
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05420012's enrollment target sits among peer trials
26 333rd of 397 higher than 63 of 397 other Heart Failure trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Heart Failure trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Gator SCALES-WHF: SubCutaneous Administration of Lasix to Eliminate Symptoms of Worsening Heart Failure
RECRUITING · Phase 4
-
Acalabrutinib Monotherapy vs Investigator's Choice of Treatment in Patients With CL Leukaemia and Heart Failure
RECRUITING · Phase 4
-
Treatment Of Atrial Fibrillation In Preserved Cardiac Function Heart Failure
RECRUITING · Phase 4
-
The STOP-MED CTRCD Trial
RECRUITING · Phase 4
-
IRONICA: IRON Repletion In Heart Failure - A Comparison of Oral and IV Approaches
RECRUITING · Phase 4
-
Efficacy Of Sodium Glucose Transporter Inhibitor (SGLT2I) In Adult Patients With Congenital Heart Disease
RECRUITING · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02646475 · 26 participants · Phase 1
Metabolic Effects of Angiotensin-(1-7)
- NCT03603223 · 26 participants · Phase 2
Pembrolizumab in Treating Participants With Leukoplakia
- NCT04063592 · 26 participants · NA
AMI Construction in Lower Extremity Residual Limbs
- NCT04906460 · 26 participants · Phase 1
Open-label Study of WVE-N531 in Patients With Duchenne Muscular Dystrophy (FORWARD-53)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI